LONDON – Spinifex Pharmaceuticals announced positive Phase II results of EMA401 in controlling neuropathic pain following herpes zoster (shingles) infection, and the company is now weighing the commercialization strategy for the product. Read More

LONDON – After marathon negotiations, SkyePharma plc reached agreement on restructuring £83 million (US$131.2 million) of bond debt, avoiding the obligation to make payments – that it could not possibly have afforded – of £68.4 million in 2013 and £21.6 million in 2014. Read More

Agennix AG is cutting more than half of its work force and shutting down a small drug development facility in Houston, in the wake of the recent failure of its lead drug talactoferrin in a Phase III trial in non-small-cell lung carcinoma (NSCLC). Read More

Although multiple treatment options are currently available for people suffering from rheumatoid arthritis (RA), there will always remain room for effective new therapies. Read More

Sanofi SA is withdrawing the leukemia drug Campath (alemtuzumab), a major bone of contention during the fractious negotiations preceding its 2011 acquisition of Genzyme Corp., in favor of rebranding the CD52-targeting antibody as Lemtrada in the planned indication of multiple sclerosis (MS). Read More

• Debiopharm Group, of Lausanne, Switzerland, treated its first patient in an open-label, Phase III trial of triptorelin pamoate 22.5 mg 6-month formulation in children with central precocious puberty. Read More